The content on this site is intended for healthcare professionals only
Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the upfront use of neoadjuvant chemotherapy in operable cT3 cN1 luminal breast cancer in the preoperative phase.
He explains the three different indications of using neoadjuvant chemotherapy and believes that there is a place for neoadjuvant chemotherapy for patients with high-grade, large and less endocrine-sensitive tumours.
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Burden and trends of breast cancer worldwide: Opportunities for prevention?
SABCS 2024: Highlights in breast cancer genomic testing
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Durable responses in aRCC, how do we optimise treatment?
